Medicare and GLP-1s: the $50 Bridge That Opened in July

The answer to “does Medicare cover Wegovy” changed on July 1, 2026, and most pages answering it are still describing the old rules. Under a temporary arrangement called the Medicare GLP-1 Bridge, several GLP-1 drugs prescribed for weight are now paid for, and eligible beneficiaries pay a flat $50 a month.^[1]

It is not a permanent benefit, and it is not Part D coverage in the ordinary sense. It deliberately runs outside the Part D payment structure, because the law that bars Medicare from covering weight-loss drugs has not changed.^[2] It runs until December 31, 2027. That end date is itself an extension: CMS lengthened the Bridge because the BALANCE model, meant to carry GLP-1 coverage into Part D, will not launch in Medicare in 2027.^[2]

Why a bridge, and not just coverage

Medicare has been barred by statute from covering drugs used for weight loss. That is why a drug like Wegovy could be covered under Part D for cardiovascular risk reduction (an approved indication that is not weight loss) while the same drug for the same person, prescribed for weight, was not covered.

The Bridge is how CMS works around that. It is a short-term demonstration operating outside the Part D benefit, so it can reach a weight-management indication the benefit itself cannot. The corollary matters. If you already get a GLP-1 covered under your Part D benefit for an indication Part D allows, you stay there, and the Bridge is not for you.

Who qualifies

You must be 18 or older and have Medicare drug coverage, and you must have met one of the following at the time GLP-1 therapy started, not necessarily today.^[1]

Three diagnoses shut the door regardless of BMI: type 2 diabetes, moderate-to-severe sleep apnea and fatty liver disease. Medicare.gov gives the reason in a parenthesis: a Part D plan may already cover a GLP-1 for those.^[1] Humana’s Medicare page draws the same line: standard Part D plans do not cover GLP-1 drugs only for weight loss, though Part D “may cover” Ozempic and Wegovy prescribed for diabetes or cardiovascular disease.^[4]

The plan types covered are broad: standalone drug plans (PDP), Medicare Advantage plans with drug coverage (MA-PD, including HMO, HMOPOS and local or regional PPO), Special Needs Plans, group waiver plans run for an employer or a union (EGWPs), and LI NET. It is nationwide, including all states and US territories.^[1]

Which drugs, and the restriction people will miss

Mounjaro and Ozempic are not on the list. That follows from the design: both carry diabetes indications, and a diabetes prescription is already a Part D matter rather than a Bridge one.

How to get it

1. Confirm you have Part D drug coverage of one of the qualifying plan types.
2. Check the criteria against when you started, not against today’s numbers, and gather what documents that.
3. A covered drug is prescribed and sent to a pharmacy. If prior authorization is requested, the prescriber completes it. Some online prescribers accept Medicare, LifeMD among them, so ask whether yours will handle the Bridge request before you book. Our list of sellers that take insurance is a place to start, but ask about Medicare by name. In 2026 CMS uses a single central processor for authorization, claims and pharmacy payment.^[2] Your own plan does not approve the request, as Aetna tells its Medicare members. Once approved, the authorization holds for refills and dose changes through December 31, 2027, unless you switch to a different GLP-1.^[1]
4. Your provider certifies the lifestyle requirement. They must confirm you are using the drug as part of a program focused on diet and exercise. This is a condition of the program, not a formality.
5. Bring your Medicare Number. The pharmacy may ask for it, or for the last four digits of your Social Security Number.^[1]

$50 against the cash market

For anyone who qualifies, $50 a month undercuts the entire cash market, including the TrumpRx prices. When we wrote this in August 2026, across the 481 compounded semaglutide prices in this register the cheapest was $65 and the median $189.99; across 435 tirzepatide prices the cheapest was $83 and the median $258. Nothing in the compounded market reached $50. The bigger difference, though, is that the Bridge supplies the approved product rather than a compounded preparation.

It ends on December 31, 2027, and CMS describes it as short-term. What follows is not settled on the current public record, so treat the $50 as a window rather than a permanent floor. Our cash-market guide covers what the alternative costs today, and Foundayo cost sets the $50 against Lilly’s self-pay ladder.

Common questions